デュトグリプチン市場：市場規模、予測、新たな洞察-2032年

Recardioが開発中のデュトグリプチン（REC-01）は、強力かつ選択的なジペプチジルペプチダーゼ4（DPP4）阻害薬です。デュトグリプチンはSC注射により投与されます。

HEAL-MIと名付けられたこの重要な国際共同試験は、左室駆出率（LVEF）を特定しないSTEMIのAMI患者4,000人を登録するもので、スクリーニングを容易にすることで、登録総数を加速します。主要エンドポイントは臨床的エンドポイント、副次的エンドポイントはQOL評価です。この助言に基づき、2022年の開始を目指した試験の準備が進められており、米国、欧州、中国という世界の主要地域で患者を登録する予定です。

今後数年間で、心筋梗塞の市場シナリオは、世界中の広範な調査と医療支出の増加により変化します。各社は、病状を治療/改善するための新たなアプローチに焦点を当てた治療法を開発し、課題を評価し、デュトグリプチンの優位性に影響を与える可能性のある機会を模索しています。他の心筋梗塞治療薬もデュトグリプチンとの厳しい市場競合が予想され、近い将来、後発の新興治療薬が上市されれば、市場に大きな影響を与えるとみられています。

当レポートでは、主要7ヶ国における心筋梗塞治療薬のデュトグリプチン市場について調査し、市場の概要とともに、競合情勢、2032年までの市場規模予測、および国別市場分析などを提供しています。

目次

第1章 レポートのイントロダクション

第2章 心筋梗塞におけるデュトグリプチンの概要

• 製品の詳細
• 臨床開発
  • 臨床研究
  • 臨床試験情報
  • 安全性と有効性
• その他の開発活動
• 製品プロファイル

第3章 競合情勢（上市済み治療法）

第4章 競合情勢（後期段階の新興治療法）

第5章 デュトグリプチン市場評価

• 心筋梗塞におけるデュトグリプチン市場の見通し
• 主要7ヶ国分析
  • 主要7ヶ国の心筋梗塞治療薬デュトグリプチンの市場規模
• 国別市場分析
  • 米国
  • ドイツ
  • 英国

第6章 SWOT分析

第7章 アナリストの見解

第8章 付録

第9章 DelveInsightのサービス内容

第10章 免責事項

第11章 DelveInsightについて

第12章 レポート購入オプション

List of Tables

• Table 1: Dutogliptin, Clinical Trial Description, 2023
• Table 2: Dutogliptin, General Description
• Table 3: Competitive Landscape (Marketed Therapies)
• Table 4: Competitive Landscape (Late-stage Emerging Therapies)
• Table 5: Dutogliptin Market Size in the 7MM, in USD million (2019-2032)
• Table 6: Dutogliptin Market Size in the US, in USD million (2019-2032)
• Table 7: Dutogliptin Market Size in Germany, in USD million (2019-2032)
• Table 8: Dutogliptin Market Size in France, in USD million (2019-2032)
• Table 9: Dutogliptin Market Size in Italy, in USD million (2019-2032)
• Table 10: Dutogliptin Market Size in Spain, in USD million (2019-2032)
• Table 11: Dutogliptin Market Size in the UK, in USD million (2019-2032)
• Table 12: Dutogliptin Market Size in Japan, in USD million (2019-2032)

List of Figures

• Figure 1: Dutogliptin Market Size in the 7MM, USD million (2019-2032)
• Figure 2: Dutogliptin Market Size in the United States, USD million (2019-2032)
• Figure 3: Dutogliptin Market Size in Germany, USD million (2019-2032)
• Figure 4: Dutogliptin Market Size in France, USD million (2019-2032)
• Figure 5: Dutogliptin Market Size in Italy, USD million (2019-2032)
• Figure 6: Dutogliptin Market Size in Spain, USD million (2019-2032)
• Figure 7: Dutogliptin Market Size in the United Kingdom, USD million (2019-2032)
• Figure 8: Dutogliptin Market Size in Japan, USD million (2019-2032)

"Dutogliptin Market Size, Forecast, and Emerging Insight - 2032" report provides comprehensive insights about dutogliptin for myocardial infarction in the seven major markets. A detailed picture of the dutogliptin for myocardial infarction in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the dutogliptin for myocardial infarction. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the dutogliptin market forecast analysis for myocardial infarction in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in myocardial infarction.

Drug Summary:

Dutogliptin (REC-01), being developed by Recardio, is a potent and selective inhibitor of dipeptidyl peptidase 4 (DPP4). Dutogliptin is administered via SC injection.

The pivotal global trial, named HEAL-MI, will enroll 4,000 AMI patients with STEMI but not specified left ventricular ejection fraction (LVEF) and with facilitated screening procedures, which will accelerate the total enrollment. The primary endpoint is a combined clinical endpoint with a quality-of-life evaluation as a secondary endpoint. Based on this advice, preparations are underway for the trial which was intended to start in 2022 and will enroll patients in the key global regions - the US, Europe, and China.

Scope of the Report:

The report provides insights into:

• A comprehensive product overview including the dutogliptin description, mechanism of action, dosage and administration, research and development activities in myocardial infarction.
• Elaborated details on dutogliptin regulatory milestones and other development activities have been provided in this report.
• The report also highlights the dutogliptin research and development activities in myocardial infarction across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around dutogliptin.
• The report contains forecasted sales of dutogliptin for myocardial infarction till 2032.
• Comprehensive coverage of the late-stage emerging therapies for myocardial infarction.
• The report also features the SWOT analysis with analyst views for dutogliptin in myocardial infarction.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Dutogliptin Analytical Perspective by DelveInsight

• In-depth Dutogliptin Market Assessment

This report provides a detailed market assessment of dutogliptin for myocardial infarction in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2026 to 2032.

• Dutogliptin Clinical Assessment

The report provides the clinical trials information of dutogliptin for myocardial infarction covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights:

• In the coming years, the market scenario for myocardial infarction is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence dutogliptin dominance.
• Other emerging products for myocardial infarction are expected to give tough market competition to dutogliptin and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of dutogliptin in myocardial infarction.
• Our in-depth analysis of the forecasted sales data of dutogliptin from 2026 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the dutogliptin in myocardial infarction.

Key Questions:

• What is the product type, route of administration and mechanism of action of dutogliptin?
• What is the clinical trial status of the study related to dutogliptin in myocardial infarction and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the dutogliptin development?
• What are the key designations that have been granted to dutogliptin for myocardial infarction?
• What is the forecasted market scenario of dutogliptin for myocardial infarction?
• What are the forecasted sales of dutogliptin in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
• What are the other emerging products available and how are these giving competition to dutogliptin for myocardial infarction?
• Which are the late-stage emerging therapies under development for the treatment of myocardial infarction?

Table of Contents

1. Report Introduction

2. Dutogliptin Overview in myocardial infarction

• 2.1. Product Detail
• 2.2. Clinical Development
  • 2.2.1. Clinical studies
  • 2.2.2. Clinical trials information
  • 2.2.3. Safety and efficacy
• 2.3. Other Developmental Activities
• 2.4. Product Profile

3. Competitive Landscape (Marketed Therapies)

4. Competitive Landscape (Late-stage Emerging Therapies)

5. Dutogliptin Market Assessment

• 5.1. Market Outlook of Dutogliptin in myocardial infarction
• 5.2. 7MM Analysis
  • 5.2.1. Market Size of Dutogliptin in the 7MM for myocardial infarction
• 5.3. Country-wise Market Analysis
  • 5.3.1. Market Size of Dutogliptin in the United States for myocardial infarction
  • 5.3.2. Market Size of Dutogliptin in Germany for myocardial infarction
  • 5.3.3. Market Size of Dutogliptin in France for myocardial infarction
  • 5.3.4. Market Size of Dutogliptin in Italy for myocardial infarction
  • 5.3.5. Market Size of Dutogliptin in Spain for myocardial infarction
  • 5.3.6. Market Size of Dutogliptin in the United Kingdom for myocardial infarction
  • 5.3.7. Market Size of Dutogliptin in Japan for myocardial infarction

6. SWOT Analysis

7. Analysts' Views

8. Appendix

• 8.1. Bibliography
• 8.2. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

12. Report Purchase Options